Iceland· IS-EU/1/23/1768/003-005
VANFLYTA
A quizartinib product containing quizartinib, registered in Iceland by Daiichi Sankyo Europe GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Quizartinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX11 (quizartinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Quizartinib · ATC L01EX11
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Quizartinib
- Manufacturer
- Daiichi Sankyo Europe GmbH
- Country
- Iceland (IS)
- ATC code
- L01EX11
- ATC class
- Quizartinib
- Defined daily dose
- 53 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Quizartinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVANFLYTADaiichi Sankyo Europe GmbH, Mnichov
- SwitzerlandVANFLYTA 26.5 mg, FilmtablettenDaiichi Sankyo (Schweiz) AG
- FinlandVANFLYTADaiichi Sankyo Europe GmbH
- FranceVANFLYTA 26,5 mg, comprimé pelliculéDAIICHI SANKYO EUROPE (ALLEMAGNE)
- IrelandVANFLYTA 26.5 mg film-coated tabletsDaiichi Sankyo Europe GmbH
- NetherlandsVANFLYTA 26,5 mg filmomhulde tablettenDAIICHI SANKYO EUROPE GmbH
- NorwayVanflytaDaiichi Sankyo Europe GmbH
- PolandVanflytaDaiichi Sankyo Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Vanflyta
- Norway · Vanflyta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a7bb62db-a413-423c-8eb4-bf4ec384fa5a GET /v1/drugs/a7bb62db-a413-423c-8eb4-bf4ec384fa5a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01EX11",
"marketed": false,
"strength": "26,5 mg",
"ma_number": "EU/1/23/1768/003-005",
"substance": "Quizartinib",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum og krabbameinslækningum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "45236"
}See everything about quizartinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.